This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Awan MJ , Gittleman H , Barnholtz-Sloan J , Machtay M , Nguyen-Tan PF , Rosenthal DI , Schultz C , Huth BJ , Thorstad WL , Frank SJ , Kim H , Foote RL , Lango MN , Shenouda G , Suntharalingam M , Harris J , Zhang Q , Le QT , Yao M
Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522
Oral Oncol. 2021 Feb 25;116 :105241
PMID: 33640577 URL: https://www.ncbi.nlm.nih.gov/pubmed/33640577
AbstractOBJECTIVES: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC). MATERIAL AND METHODS: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively. RESULTS: The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c = 0.66, c = 0.66 and c = 0.73, respectively. External validation of these nomograms yielded c = 0.59, c = 0.70, and c = 0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome. CONCLUSIONS: We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data.
Notes1879-0593 Awan, Musaddiq J Gittleman, Haley Barnholtz-Sloan, Jill Machtay, Mitchell Nguyen-Tan, Phuc Felix Rosenthal, David I Schultz, Christopher Huth, Bradley J Thorstad, Wade L Frank, Steven J Kim, Harold Foote, Robert L Lango, Miriam N Shenouda, George Suntharalingam, Mohan Harris, Jonathan Zhang, Qiang Le, Quynh-Thu Yao, Min NRG Oncology Group Journal Article England Oral Oncol. 2021 Feb 25;116:105241. doi: 10.1016/j.oraloncology.2021.105241.